HC Wainwright Forecasts Lower Earnings for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Equities research analysts at HC Wainwright dropped their Q3 2025 earnings estimates for Sensus Healthcare in a research report issued on Tuesday, August 12th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.12) for the quarter, down from their previous estimate of ($0.02). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.43) EPS, Q1 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.09 EPS and FY2026 earnings at $0.01 EPS.

A number of other brokerages have also recently weighed in on SRTS. Lake Street Capital dropped their price target on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Wall Street Zen cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a research report on Sunday, June 22nd. Finally, Maxim Group dropped their price target on shares of Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, May 19th.

Sensus Healthcare Trading Up 0.6%

Sensus Healthcare stock opened at $3.44 on Thursday. Sensus Healthcare has a 12-month low of $3.03 and a 12-month high of $9.33. The stock has a market cap of $56.55 million, a P/E ratio of -57.33 and a beta of 1.34. The company has a 50-day moving average price of $4.72 and a 200 day moving average price of $4.91.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.07). Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%. The firm had revenue of $7.32 million for the quarter, compared to analyst estimates of $9.30 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. American Century Companies Inc. boosted its stake in shares of Sensus Healthcare by 12.7% in the first quarter. American Century Companies Inc. now owns 22,440 shares of the company’s stock valued at $106,000 after purchasing an additional 2,520 shares during the period. Geode Capital Management LLC boosted its stake in shares of Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock valued at $730,000 after purchasing an additional 3,766 shares during the period. Sachetta LLC boosted its stake in shares of Sensus Healthcare by 3.0% in the second quarter. Sachetta LLC now owns 128,675 shares of the company’s stock valued at $610,000 after purchasing an additional 3,788 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of Sensus Healthcare in the fourth quarter valued at approximately $27,000. Finally, Chapin Davis Inc. boosted its stake in shares of Sensus Healthcare by 50.0% in the first quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $71,000 after purchasing an additional 5,000 shares during the period. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.